Pradama Inc. is a pharmaceutical company focused on the development of drugs for bone diseases and disorders.

Pradama's founder is credited in the literature with the first bone-targeting drug delivery attempt. Our therapeutically neutral, orally available, small molecule bone-targeting agents can be readily coupled to a variety of bone active agents.

We are using our bone-targeting agents to create our own drug products. Additionally, we are pursuing corporate partnerships.

For more information, please contact:

Kevyn Merten, Ph.D.
Associate Director of Research Operations
kmerten@pradama.com
(502) 569-1020 ext. 307
Andrew Steen
Vice President of Business Development
asteen@pradama.com
(502) 569-1020 ext. 304